Wells Fargo & Company MN boosted its holdings in shares of Fresenius Medical Care AG & Co. (NYSE:FMS) by 221.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 272,686 shares of the company’s stock after buying an additional 187,977 shares during the period. Wells Fargo & Company MN’s holdings in Fresenius Medical Care AG & Co. were worth $14,022,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of FMS. Acadian Asset Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. during the 2nd quarter worth about $106,000. Mount Yale Investment Advisors LLC bought a new stake in Fresenius Medical Care AG & Co. during the 2nd quarter valued at approximately $192,000. Cibc Bank USA bought a new stake in Fresenius Medical Care AG & Co. during the 3rd quarter valued at approximately $215,000. Iberiabank Corp bought a new stake in Fresenius Medical Care AG & Co. during the 3rd quarter valued at approximately $258,000. Finally, Cornerstone Wealth Management LLC bought a new stake in Fresenius Medical Care AG & Co. during the 2nd quarter valued at approximately $276,000. 2.45% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care AG & Co. stock opened at $39.23 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $25.06 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 1.89 and a beta of 1.10. Fresenius Medical Care AG & Co. has a 12 month low of $37.47 and a 12 month high of $57.94.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Tuesday, October 30th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.58 by $0.11. The firm had revenue of $4.72 billion during the quarter. Fresenius Medical Care AG & Co. had a return on equity of 10.87% and a net margin of 11.71%. As a group, analysts expect that Fresenius Medical Care AG & Co. will post 2.41 earnings per share for the current fiscal year.

Several analysts recently weighed in on FMS shares. UBS Group upgraded Fresenius Medical Care AG & Co. from a “neutral” rating to a “buy” rating and set a $82.00 target price for the company in a research note on Friday, October 26th. HSBC upgraded Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. SunTrust Banks decreased their target price on Fresenius Medical Care AG & Co. to $46.00 and set a “buy” rating for the company in a research note on Tuesday, November 20th. TheStreet downgraded Fresenius Medical Care AG & Co. from a “b-” rating to a “c+” rating in a research note on Monday, November 12th. Finally, Zacks Investment Research restated a “hold” rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, November 13th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $62.00.

WARNING: “Fresenius Medical Care AG & Co. (FMS) Position Lifted by Wells Fargo & Company MN” was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/fresenius-medical-care-ag-co-fms-position-lifted-by-wells-fargo-company-mn/2668295.html.

Fresenius Medical Care AG & Co. Profile

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

See Also: Moving Average (MA)

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.